Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate

Author: Benzinga Newsdesk | May 13, 2024 08:27am
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.722 thousand which missed the analyst consensus estimate of $400.000 thousand by 23.57 percent. This is a 61.28 percent decrease over sales of $789.635 thousand the same period last year.

Posted In: ENSC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist